Comment on Khan S P Khan, et al. (J Pak Med Assoc. 74: 1654-1658, September 2024) Role of Oral Hypoglycaemic Drugs in Preventing Complications in Non-Alcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus

Abstract

Dear Editor, I recently came across the paper "Role of OralHypoglycaemic Drugs in Preventing Complications inNon-Alcoholic Fatty Liver Disease with Type 2 DiabetesMellitus" in your esteemed journal. The study effectivelyhighlights the significance of empagliflozin andmetformin in reducing fatty liver changes and liverenzymes in NAFLD patients with type 2 diabetes mellitus.Current data strongly supports empagliflozin, an SGLT2inhibitor, in effectively managing blood glucose levels,reducing hepatic steatosis, and lowering cardiovascularrisk among these patients¹.Nevertheless, the study's restricted sample size and highpatient dropout rate curtail the broad applicability of thefindings. It would be advantageous to conduct larger,multicenter trials with extended follow-up periods tothoroughly investigate the sustained impact of thesedrugs on hepatic and metabolic outcomes. Such datawould substantially enhance clinical guidelines formanaging NAFLD in T2DM patients.

Continued...